DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

92260 Fontenay Aux Roses (France)

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s). I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOUNDS DERIVED FROM OXINDOLES AND THEIR THERAPEUTIC APPLICATION IN CANCER TREATMENT

	and the specification of v (check one)	was filed on and was ame was describe		
	I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above. I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56.			
	application(s) for patent at least one other countr of the application on whi	or inventor's certificate, or other than the United Stoch priority is claimed. I/W	itle 35, United States Code §119(a)-(d) or 365 (b) of any foreign or 365(a) of any PCT international application which designated ates of America, listed below and having a filing date before that e have also identified below any foreign application for patent or t of the application on which priority is claimed:	
Foreign	01 03408	France	13/March/2001	
Priority:	Number	Country	Day/Month/Year Filed	
			·	
Prior Foreign Appln(s):	Number	Country	Day/Month/Year Filed	
	I/We hereby claim the application(s) listed bel		United States Code §119(e) of any United States Provisional	
	Number	Filing Date		
	I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United Sapplication(s) or international application designating the United States listed below and, insofar as the samtter of each of the claims of this application is not disclosed in the prior United States application in the material by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to discinformation which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 became available between the filing date of the prior application and the national or PCT international filing of this application.			
	PCT/FR02/00852 Application Serial No.	March 11, 2002 Filing Date	Pending Status (Patented, Pending)	
and belief a	re believed to be true; and so made are punishable	d further that these statem by fine or imprisonment, o	knowledge are true and that all statements made on information ents were made with the knowledge that willful false statements or both, under Title 18, United States code §1001, and that such ation or any patent issued thereon.	
Inventors(s)	: Additional name	es and signatures are attac	ched.	
1. Full name:	Cécile COMBEAU		2. Full name: Patrick MAILLIET	
			Signature:	
Signature: Date:			Date:	
Country of Citizenship: France			Country of Citizenship: France	
Residence: Fontenay Aux Roses/France			Residence: Fontenay Sous Bois/France	
(City and State/City and Country only) P. O. Address: 98 rue Boucicaut			(City and State/City and Country only) P. O. Address: 87 rue Dalayrac	

94120 Fontenay Sous Bois (France)

3. Full name: Marielle CHIRON	4. Full name:
Signature:	Signature:
Date:	Date:
Country of Citizenship: France	Country of Citizenship:
Residence: Paris/France (City and State/City and Country only)	Residence:(City and State/City and Country only)
P. O. Address: 13 rue Castagnary 75015 Paris (France)	P. O. Address:
5. Full name:	6. Full name:
Signature:	Signature:
Date:	Date:
Country of Citizenship:	Country of Citizenship:
Residence:(City and State/City and Country only)	Residence:(City and State/City and Country only)
P. O. Address:	P. O. Address:

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-2387
Telefax (908) 231-2626

Aventis Docket No. ST01010 US CNT